SC Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior PK Compared to IV KEYTRUDA in Pivotal 3475A-D77 Trial April 2, 2025
FAILED TRIAL: Ph 3 ARTISTRY-7 Trial of Nemvaleukin + KEYTRUDA in Patients with Platinum-Resistant Ovarian Cancer did not achieve a statistically significant improvement in OS April 2, 2025
Primary Endpoint Met in Pivotal Ph 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer April 2, 2025
Ph 3 Study Design Finalized with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer April 2, 2025
TIVDAK (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer April 2, 2025
RYBREVANT (amivantamab-vmjw) + LAZCLUZE (lazertinib) outperform osimertinib with a significant OS benefit in patients with EGFR-mutated NSCLC April 2, 2025
Positive CHMP Opinion for the SC Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications April 2, 2025
FDA approves Pluvicto for earlier use before chemotherapy in PSMA-positive metastatic CRPC April 2, 2025
Relmada Therapeutics Licenses Ph 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma April 2, 2025
First Patient Dosed in the Ph 3 Registrational Trial of ICP-248 + Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China April 2, 2025
In LAURA Ph 3 trial, Tagrisso continues to demonstrate improved OS trend in unresectable, Stage III setting April 2, 2025
75.5% CR at any time in Ph 3 study of cretostimogene monotherapy for high-risk BCG-unresponsive NMIBC with carcinoma in situ (CIS) April 2, 2025
Both Prolonged Median OS and Long Tail of Survival in Ph 2a Trial of CAN-2409 in Advanced NSCLC Patients Non-Responsive to ICI Treatment Reported April 2, 2025
FDA Clears IND Application for Ph 1 Trial of RB-164 for Hematologic and Solid Malignancies April 2, 2025
US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma April 2, 2025
Positive CHMP Opinion for Neoadjuvant Opdivo + Chemo Followed by Surgery and Adjuvant Opdivo for Resectable NSCLC in Patients with Tumor Cell PD-L1 Expression ≥1% April 2, 2025
Calquence plus chemoimmunotherapy recommended for approval in the EU by CHMP for 1L MCL April 2, 2025
U.S. FDA Approves CABOMETYX for Patients with Previously Treated Advanced Neuroendocrine Tumors April 2, 2025
Imfinzi approved in the US as perioperative immunotherapy for patients with muscle-invasive bladder cancer April 2, 2025
